Education
About Us
Working with TipRanks
Follow Us
Emyria Ltd (AU:EMD)
ASX:EMD
EMD Stock Chart & Stats
AU$0.06
>-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.06
>-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.08
Previous CloseN/A
Volume148.47K
Average Volume (3M)4.06M
Market Cap
AU$43.55M
Enterprise ValueAU$29.17M
Total Cash (Recent Filing)AU$3.57M
Total Debt (Recent Filing)AU$613.50K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding806,522,340
10 Day Avg. Volume2,903,931
30 Day Avg. Volume4,056,978
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.37
Price to Sales (P/S)9.01
P/FCF Ratio-4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Model (clinical Services + Research)Emyria operates two complementary revenue streams: fee-for-service specialist clinics and contracted research/trial income. This structural diversification can smooth cash flow timing, leverage clinic infrastructure for trial delivery, and create multiple pathways for long-term commercialization or partner revenue.
Low Leverage And Equity-backed Balance SheetA debt-to-equity ratio near 0.12 indicates low financial leverage, reducing interest burden and financial fragility. This durable balance-sheet characteristic preserves capacity to raise capital, absorb operational shocks, or fund trial activity without excessive debt costs while cash flows recover.
Strategic Positioning In Mental Health And Psychedelics R&DEmyria’s clinic-led model combined with active involvement in psychedelic-assisted therapy trials aligns with growing structural interest in novel mental-health treatments. Clinic access supports patient recruitment and real-world data generation, strengthening long-term prospects for partnerships or product development.
Bears Say
Declining Revenue TrendMaterial top-line contraction (mid-20% decline most recently and multi-period negative growth) reduces operating scale and weakens unit economics for clinics and trial sites. Continued revenue decline constrains reinvestment in R&D, increases per-unit fixed costs, and raises financing need risk over coming months.
Persistent Negative Profit MarginsLoss-making results at gross, EBIT/EBITDA and net levels imply structural profitability issues, not just timing. Sustained negative margins erode retained capital, limit ability to self-fund trials or clinic expansion, and mean strategic progress likely depends on operational turnaround or external funding.
Negative Operating And Free Cash Flow (cash Burn)Persistent negative operating and free cash flows signal ongoing cash burn despite reported FCF growth rate. Continued cash deficits reduce strategic optionality, increase reliance on equity or debt financing, and heighten dilution or funding-risk over the medium term unless operations generate positive cash conversion.
Emyria Ltd News
EMD FAQ
What was Emyria Ltd’s price range in the past 12 months?
Emyria Ltd lowest share price was AU$0.02 and its highest was AU$0.08 in the past 12 months.
What is Emyria Ltd’s market cap?
Emyria Ltd’s market cap is AU$43.55M.
When is Emyria Ltd’s upcoming earnings report date?
Emyria Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 10 days.
How were Emyria Ltd’s earnings last quarter?
Emyria Ltd released its earnings results on Aug 27, 2025. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Emyria Ltd overvalued?
According to Wall Street analysts Emyria Ltd’s price is currently Overvalued.
Does Emyria Ltd pay dividends?
Emyria Ltd does not currently pay dividends.
What is Emyria Ltd’s EPS estimate?
Emyria Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emyria Ltd have?
Emyria Ltd has 806,522,340 shares outstanding.
What happened to Emyria Ltd’s price movement after its last earnings report?
Emyria Ltd reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4%.
Which hedge fund is a major shareholder of Emyria Ltd?
Currently, no hedge funds are holding shares in AU:EMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emyria Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
126.66%
12-Months-Change
Fundamentals
Return on Equity
-81.30%
Trailing 12-Months
Asset Growth
21.99%
Trailing 12-Months
Company Description
Emyria Ltd
Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops cannabinoid-based medicines, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and irritable bowel syndrome; and EMD-RX7 for multiple medical conditions. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.
Technical Analysis
Options Prices
Currently, No data available
---